Диссертация (Фибрилляции предсердий - предикторы прогрессирования, эволюция клинического течения и выбор стратегии лечения), страница 37
Описание файла
Файл "Диссертация" внутри архива находится в папке "Фибрилляции предсердий - предикторы прогрессирования, эволюция клинического течения и выбор стратегии лечения". PDF-файл из архива "Фибрилляции предсердий - предикторы прогрессирования, эволюция клинического течения и выбор стратегии лечения", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой докторскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени доктора медицинских наук.
Просмотр PDF-файла онлайн
Текст 37 страницы из PDF
62–73.253. Nattel S. From guidelines to bench: implications of unresolvedclinical issues for basic investigations of atrial fibrillation mechanisms. / Nattel S.// Can J Cardiol – 2011-Vol 27(1)- P.19–26.254. Nattel S. New ideas about atrial fibrillation 50 years on. / Nattel S //Nature.- 2002- Vol 415(6868)- P.219–226.255. Neef S. CaMKII-dependent diastolic SR Ca2+leak and elevateddiastolic Ca2+ levels in right atrial myocardium of patients with atrialfibrillation./ Neef S. [et al.] // Circ Res. – 2010-Vol 106(6)-P.1134–1144.250256.
Nieuwlaat R. Atrial fibrillation management: a prospective survey inESC member countries: the Euro Heart Survey on Atrial Fibrillation./ NieuwlaatR. [et al.] // Eur Heart J – 2005- Vol 26- P. 2422–2434.257. Nishida K. Mechanisms of atrial tachyarrhythmias associated withcoronary artery occlusion in a chronic canine model. / Nishida K. [et al.]//Circulation.- 2011-Vol 123(2)- P.137–146.258. Nishida K. Animal models for atrial fibrillation: clinical insights andscientific opportunities.
/ Nishida K. [et al.]//Europace.- 2010-Vol 12(2)-P.160–172.259. Nodari S. Effects of Polyunsaturated Fatty Acids n-3 (PUFA n-3) inthe prophylaxis of atrial fibrillation relapses after external electric cardioversion/Nodari S [et al.] // Eur Heart J- 2006-Vol 27 –P.887-90260. Ogrodnik J. Increased Ca2+ leak and spatiotemporal coherence ofCa2+ release in cardiomyocytes during beta-adrenergic stimulation./ Ogrodnik J,Niggli E. // J Physiol. – 2010- Vol 588- P.225–242.261. Ogunsua AA. Atrial Fibrillation and Hypertension: Mechanistic,Epidemiologic, and Treatment Parallels./ Ogunsua AA. [et al.]//MethodistDebakey Cardiovasc J.- 2015- Vol 11(4)- P.228-34.262. Okin PM.
Regression of electrocardiographic left ventricularhypertrophy and decrease incidence of new-onset atrial fibrillation in patientswith hypertension. / Okin PM. [et al.] // JAMA.- 2006 – Vol 296(10)- P.1242-8.263. Olesen JB. Stroke and bleeding in atrial fibrillation with chronickidney disease./ Olesen JB. [et al.] // N Engl J Med -2012-Vol 367(7)- P.625-35.264. Opolski G.
Investigators of the Polish How to Treat Chronic AtrialFibrillation Study. Rate control vs rhythm control in patients with nonvalvularpersistent atrial fibrillation: the results of the Polish How to Treat Chronic AtrialFibrillation (HOT CAFE) Study. / Opolski G. [et al.] // Chest.- 2004- Vol 126(2)P.476-86.251265.
Parvez B. Symptomatic Response to Antiarrhythmic Drug TherapyIs Modulated by a Common Single Nucleotide Polymorphism in AtrialFibrillation / Parvez B. [et al.] // J Am Coll Cardiol. – 2012- Jun 7-p.789-97.266. Patti G. Randomized trial of atorvastatin for reduction оfpostoperative atrial fibrillation in patients undergoing cardiac surgery: results ofthе ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia Aftercardiac surgery) study. / Patti G.
[et al.]// Circulation- 2006-vol 114- P.1455–1461.267. Pedersen OD. Trandolapril reduces the incidence of atrial fibrillationafter acute myocardial infarction in patients with left ventricular dysfunction./Pedersen OD. [et al.] //Circulation- 1999- Vol 100- P.376–80.268. Padfield, G.J. Progression of paroxysmal to persistent atrialfibrillation: Canadian Registry of Atrial Fibrillation 10-year follow-up. / Padfield,G.J. [et al.] //Heart Rhythm.
– 2017- Vol 23- P.213-223.269. Piccini JP. Outcomes registry for better informed treatment of atrialfibrillation: rationale and design of ORBIT-AF./ Piccini JP. [et al.] // Am Heart J– 2011- Vol 162- P.606–12.270. Piccini JP. Incidence and prevalence of atrial fibrillation andassociated mortality among Medicare beneficiaries, 1993-2007/ Piccini JP.
[et al.]// Circ Cardiovasc Qual Outcomes- 2012-Vol 5-P. 85-93.271. Pisters R. A novel user-friendly score (HAS-BLED) to assess 1-yearrisk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey./Pisters R [et al.] //Chest.- 2010 – Vol 138(5)-P.1093-100272. Pizzetti F. Incidence and prognostic significance of atrial fibrillationin acute myocardial infarction: the GISSI-3 data./ Pizzetti F.
[et al.] // Heart2001- Vol 86- P. 527–32.273. Platonov PG. Structural abnormalities in atrial walls are associatedwith presence and persistency of atrial fibrillation but not with age./ Platonov PG[et al.] // J Am Coll Cardiol. - 2011 – Vol 58(21)- P.2225-32.252274. Rader F.
Effect of early statin therapy on risk of atrial fibrillationafter coronary artery bypass grafting with or without concomitant valve surgery. /Rader F. [et al.] //Am. J. Cardiol. – 2011 – Vol 108 (2)- P. 220–2.275. Reilly SN. Atrial sources of reactive oxygen species vary with theduration and substrate of atrial fibrillation: implications for the antiarrhythmiceffect of statins./ Reilly SN. [et al.] //Circulation – 2011-Vol 124- P.1107–17.276. Reinhold D. The costs of atrial fibrillation in patients withcardiovascular comorbidities — a longitudinal analysis of German healthinsurance data.
/ Reinhold D. [et al.]// Europace. - 2011 – Vol 13(9)- P.1275-80.277. Rezaei Y. Statin antiarrhythmic effect on atrial fibrillation in statinnaive patients undergoing cardiac surgery: a meta-analysis of randomizedcontrolled trials./ Rezaei Y. [et al.] //J Cardiovasc Pharmacol Ther – 2016- Vol21- P.167–76.278. Rodriguez F. Racial and ethnic differences in atrial fibrillation riskfactors and predictors in women: findings from the Women’s Health Initiative. /Rodriguez F.
[et al.] //Am Heart J – 2016- Vol 176-P. 70–7.279. Roldán V. Plasma von Willebrand factor levels are an independentrisk factor for adverse events including mortality and major bleeding inanticoagulated atrial fibrillation patients. / Roldán V. [et al.] //J Am Coll Cardiol.-2011 –Vol 57(25)- P. 2496-504.280. Roy D.
Rhythm control versus rate control for atrial fibrillation andheart failure. / Roy D. [et al.] // N Engl J Med – 2008- Vol 358- P.2667-2677.281. Ruilope LM. Left ventricular hypertrophy and clinical outcomes inhypertensive patients. / Ruilope LM.
[et al.]// Am J Hypertens. 2008- Vol21(5)- P.500-8.282. Salehian O. Impact of ramipril on the incidence of atrial fibrillation:results of the Heart Outcomes Prevention Evaluation study. / Salehian O. [et al.]//Am Heart J- 2007- Vol 154- P.448 –53.253283. Sankaranarayanan R. Comparison of atrial fibrillation in the youngversus that in the elderly: A review / Sankaranarayanan R. [et al.] // CardiologyResearch and Practice. – 2013- Article ID 976976.284. Santangeli P.
Usefulness of statins in preventing atrial fibrillation inpatients with permanent pacemaker: a systematic review. / Santangeli P. [et al.] //Europace 2010- Vol 12- P. 649–654.285. Savelieva I. Upstream therapies for management of atrial fibrillation:review of clinical evidence and implications for European Society of Cardiologyguidelines. Part I: primary prevention. / Savelieva I. [et al.] //Europace. – 2011Vol 13(3)-P.308-28.286. Savelieva I.
Statins and polyunsaturated fatty acids for treatment ofatrial fibrillation. / Savelieva I. [et al.]// Nat Clin Pract Cardiovasc Med – 2008-Vol 5-P. 30–41.287. Savelieva I. Primary and secondary prevention of atrial fibrillationwith statins and polyunsaturated fatty acids: review of evidence and clinicalrelevance./ Savelieva I. [et al.]// Naunyn Schmiedebergs Arch Pharmacol –2010- Vol 381-P. 1–13.288. Schaer BA.
Risk for incident atrial fibrillation in patients whoreceive antihypertensive drugs: a nested case-control study. / Schaer BA. [et al.]//Ann Inter Med. - 2010 – Vol 152(2)- P.78-84.289. Schmieder RE Reduced incidence of new-onset atrial fibrillationwith angiotensin II receptor blockade: the VALUE trial./ Schmieder RE [et al.]// J Hypertens – 2008- Vol 26-P.403–11.290. Schmutz M. Low prevalence of atrial fibrillation in asymptomaticadults in Geneva, Switzerland./ Schmutz M. [et al.]// Europace -2010-Vol 12P.475-81.291. Schnabel RB. Development of a risk score for atrial fibrillation(Framingham Heart Study): a community-based cohort study.
/ Schnabel RB. [etal.] // Lancet - 2009- Vol 373- P.739–45.254292. Schneider M.P. Prevention of atrial fibrillation by renin–angiotensinsystem inhibition a meta-analysis. / Schneider M.P. [et al.] // JACC – 2010- Vol55- P. 2299–2307.293. Schoonderwoerd BA. Electrical and structural remodeling: role inthe genesis and maintenance of atrial fibrillation./ Schoonderwoerd BA. [et al.]// Prog Cardiovasc Dis. -2005 –Vol 48(3)-P. 153-68.294. Schoonderwoerd BA. New risk factors for atrial fibrillation: causesof “not–so–lone atrial fibrillation.” /Schoonderwoerd BA. [et al.] // Europace.
2008- Vol 10(1)- P.668–673.295. Schotten U. Pathophysiological mechanisms of atrial fibrillation: Atranslational appraisal./ Schotten U. [et al.]// Physiological Reviews. – 2011 -Vol91- P.265–325.296. Sciarretta S. Independent association of ECG abnormalities withmicroalbuminuria and renal damage in hypertensive patients without overtcardiovascular disease: data from Italy-Developing Education and awareness onMicroAlbuminuria in patients with hypertensive Disease study./ Sciarretta S.
